Dual-ligand PROTACS mediate superior target protein degradation in vitro and therapeutic efficacy in vivo

Proteolysis targeting chimeras (PROTACs) are revolutionizing the drug development landscape due to their unique ability to selectively degrade disease-associated proteins. Conventional PROTACs are bivalent entities that induce ubiquitination and subsequent...